Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Axalta Coating Systems

Maxim Integrated Products

The S&P 500 index posted a 7.2% yearly increase in its annual earnings per share over the past five years through Dec.

3 Stocks That Have Grown Earnings Fast

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today released its 2019 Corporate Responsibility Report. The report, published annually, details progress towards realizing the company’s Corporate Responsibility priorities and goals, including driving the sustainability of products and operations, improving access to care for the underserved and fostering a best place to work. The report published today includes developments made

Baxter Publishes 2019 Corporate Responsibility Report, Highlighting Efforts to Make a Meaningful Difference as a Leading Global Corporate Citizen

Avista

Ennis

Federated Hermes

Pinnacle West Capital

Nasdaq is up and stocks are dropping ahead of the Federal Reserve’s meeting later this afternoon. Unless you’re investing in tech stocks, there’s been plenty of ups and downs, with little telling when normalcy will return.

Top Stocks To Buy Prior To Fed Meeting

Campbell Soup

Stocks are likely to rise; here are a pair of trading selections.

Stocks This Week: Buy Baxter Travenol And Campbell Soup

Baxter (BAX) reported earnings 30 days ago. What's next for the stock?

Why Is Baxter (BAX) Up 1.4% Since Last Earnings Report?

Baxter (BAX) receives the CE marking and regulatory approval for the Evo IQ Syringe Infusion system that will help in optimizing efficiency for clinicians.

Baxter Receives CE Marking for Evo IQ Syringe Infusion System

Allstate

Morgan Stanley

T-Mobile US

United Rentals

With earnings for the first quarter all but over, Wall Street analysts are turning their attention to the second and third quarters of 2020.

Goldman Sachs Out With Top Tactical Stocks to Buy for the Next 2 Quarters

Ameren Corp (AEE) CEO Warner Baxter on Q1 2020 Results - Earnings Call Transcript

Baxter Could Come Out Of The Pandemic Stronger Than Ever

Kontoor Brands Inc

Kontoor Brands, Inc. (KTB) CEO Scott Baxter on Q1 2020 Results - Earnings Call Transcript

Baxter International Inc. BAX, -0.64% said Tuesday it was raising its quarterly dividend by 11%, to 24.5 cents a share from 22 cents.

Baxter boosts dividend by 11%, but still yields less than health care ETF

Baxter International Inc. (BAX) CEO Joe Almeida on Q1 2020 Results - Earnings Call Transcript

The giant healthcare company saw increased demand in Q1 for several products due to the coronavirus pandemic.

Baxter Beats Q1 Estimates as COVID-19 Boosts Sales

Amedisys

Jack Henry & Associates

Johnson & Johnson

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

It’s been 100 years since the United States and the world has encountered a pandemic like COVID-19.

5 Stocks to Buy Now for a W-Shaped Recovery With a Long Recession

Boston Scientific

Based on historical performance, Boston Scientific appears to be an attractive bet compared to Baxter International for growth after the current COVID-19 crisis winds down.The current coronavirus crisis will likely impact medical devices companies on two fronts, 1. supply chain disruptions, and.

Sell Baxter International To Buy Boston Scientific?

Coronavirus patients in intensive care units are using more dialysis fluids than anyone expected.

COVID-19 Has U.S. Hospitals Scrambling to Stock Dialysis Supplies

Baxter International is building a base and near a possible buy zone ahead of its next quarterly earnings report, expected on or around Apr. 30.
The post Medical Product Maker Baxter Near Buy Zone, Hiring Employees; Earnings Due appeared first on Investor's Business Daily.

Medical Product Maker Baxter Near Buy Zone, Hiring Employees; Earnings Due

Baxter (BAX) Up 2.7% Since Last Earnings Report: Can It Continue?

Carvana

Cracker Barrel Old Country Store

Energy Transfer LP Unit

HD Supply Hlds

MGM Resorts

OPKO Health

Schlumberger

SYNNEX

Union Pacific

Insider buying can be an encouraging signal for potential investors. A number of insiders made return trips to the buy windows last week.

Notable Insider Buys In The Past Week: Carvana, MGM And More

Baxter (BAX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Baxter (BAX) Looks Good: Stock Adds 5.1% in Session

Baxter (BAX) issues strong guidance for the first quarter of 2020.

Here's Why You Should Hold Onto Baxter (BAX) Stock for Now

Baxter International Inc. (BAX) CEO Joe Almeida on Q4 2019 Results - Earnings Call Transcript

The healthcare giant's medication delivery business provided its strongest growth in Q4.

What's Behind Baxter International's Better-Than-Expected Q4 Results

Baxter's (BAX) fourth-quarter earnings benefit from higher revenues, solid segmental performance and growth in APAC.

Baxter (BAX) Q4 Earnings Beat Estimates, Revenues In Line

Baxter (BAX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

News for Baxter Stock (BAX)